AMPK (AMP-activated protein kinase) is an enzyme that plays a role in cellular energy homeostasis.It is made up of three proteins (subunits), which when combined form a useful enzyme. The overall result of AMPK activation is stimulation of skeletal muscle fatty acid oxidation and muscle glucose uptake by pancreatic beta-cells. This is offset by inhibition of cholesterol, lipogenesis, and triglyceride synthesis, inhibition of adipocyte lipolysis, and stimulation of hepatic fatty acid oxidation and ketogenesis. As a metabolic master switch, AMPK controls a number of intracellular processes, such as the uptake of glucose by cells, the -oxidation of fatty acids, and the GLUT4 and mitochondrial biogenesis.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V70222 | AMPK-α1β1γ1 activator 1 | 1943510-86-8 | AMPK-α1β1γ1 activator 1 (M1) is the acylglucuronide metabolite of the Indole-3-cancer-based AMPK activator. |
|
V2166 | ASP4132 tosylate | 1640294-30-9 | ASP4132 tosylate (ASP-4132) is an oral bioavailable AMPK activator (EC50 = 18 nM) with potential anticancer activity. |
|
V88832 | Asteltoxin | 79663-49-3 | Asteltoxin is an extracellular vesicle (EV) inhibitor that inhibits mitochondrial ATP synthase and mTORC1 activation. |
|
V2440 | BC1618 | 2222094-18-8 | BC1618, an orally bioactive Fbxo48 inhibitor, stimulates Ampk signaling (preventing activated pAmpkα from being degraded by the Fbxo48-mediated proteasome). |
|
V52531 | Bempedoic acid-d4 (ETC-1002-d4; ESP-55016-d4) | 2408131-70-2 | Bempedoic acid-d4 is the deuterated marker of Bempedoic acid. |
|
V56183 | Bempedoic acid-d5 (ETC-1002-d5; ESP-55016-d5) | 2408131-71-3 | Bempedoic acid-d5 is the deuterated form of Bempedoic acid. |
|
V78668 | CB1R/AMPK modulator 1 | 2711012-08-5 | CB1R/AMPK modulator 1 (Compound 38-S) is an orally bioactive CB1R/AMPK modulator with a Ki of 0.81 nM and a CB1R IC50 of 3.9 nM. |
|
V52231 | COH-SR4 | 73439-19-7 | COH-SR4 is an AMPK activator. |
|
V98107 | Ethyl (E)-ferulate | 28028-62-8 | Ethyl (E)-ferulate is an activator of the AMPK/Nrf2 signaling pathway and can alleviate lipopolysaccharide-induced acute lung injury. |
|
V3967 | EX-229 | 1219739-36-2 | EX229 (EX-229; AMPK Activator 991), a benzimidazole analog, is a novel, potent and allosteric AMPK (AMP-activated protein kinase) activator with Kd values of 0.06 μM, 0.06 μM and 0.51 μM for α1β1γ1, α2β1γ1 and α1β2γ1 in biolayer interferometry, respectively. |
|
V0249 | GSK621 | 1346607-05-3 | GSK621 is a novel, potent and selective activator of AMP-activated protein kinase (AMPK) with potential antitumor activity. |
|
V0250 | HTH-01-015 | 1613724-42-7 | HTH-01-015 is a novel, potent and selective inhibitor of NUAK1( (NUAK family SnF1-like kinase-1)which can serve as useful chemical probes to delineate the biological roles of the NUAK kinases. |
|
V80316 | HTH-02-006 | HTH-02-006 is a NUAK2 inhibitor (IC50=126nM). | |
|
V84330 | IND 1316 | 1888473-12-8 | |
|
V51942 | IQZ23 | 2415643-79-5 | IQZ23 inhibits adipocyte differentiation by activating AMPK signaling pathway. |
|
V55744 | Kazinol U | 1238116-48-7 | Kazinol U inhibits melanogenesis by inhibiting tyrosinase-related proteins through AMPK activation. |
|
V88834 | KHKI-01128 | KHKI-01128 is a NUAK2 inhibitor with IC50 of 0.024 μM. | |
|
V88837 | Lipid-lowering agent-2 | Lipid-lowering agent-2 (Compound 14d) is an orally effective lipid-lowering agent with an EC50 of 0.06 μM. | |
|
V40864 | Lixumistat (IM156) | 1422365-93-2 | IM156 (IM-156; IM 156;HL-156A;HL156A) is a metformin/biguanideanalogwith potential anticancer and neuroprotective activity. |
|
V39112 | Lixumistat (IM156; HL156A; HL271) acetate | 1422365-94-3 | IM156 (also known as HL-156A; Lixumistat; HL-271) is a metforminderivative thac acts as a novel and highly potent AMPK activator that increases AMPK phosphorylation. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
